Celgene K.K., a Bristol Myers Squibb Company, JP Tower, 2-7-2 Marunouchi Chiyoda-ku, Tokyo 100-7010, Japan.
National Cancer Center Hospital, Tokyo, Japan.
Future Oncol. 2021 Feb;17(4):455-469. doi: 10.2217/fon-2020-0832. Epub 2020 Oct 6.
To evaluate comparative effectiveness of rituximub (R)-based versus non-R-based therapies for follicular lymphoma patients in Japan, where limited studies have been reported. Patients who received R-based index regimens were propensity score matched to those who did not receive R, based on patient baseline attributes and clinical characteristics using Japanese retrospective claims database to assess clinical and economic outcomes. A total of 1947 patients remained in the overall follicular lymphoma cohorts: 1294 receiving an R-based and 653 a non-R-based regimen. Patients on R-based therapy underwent fewer hospitalizations and had a shorter length of stay, but had higher costs during the first year of intensive R-based therapy. Improved clinical outcomes were associated with patients who were younger, female and chose R-based regimens in first index line.
为了评估日本滤泡性淋巴瘤患者中基于利妥昔单抗（R）的治疗与非 R 治疗方案的疗效比较，在日本，相关研究报告十分有限。在这项日本回顾性索赔数据库研究中，根据患者基线特征和临床特征，对接受 R 为基础的指数治疗方案的患者和未接受 R 的患者进行倾向评分匹配，以评估临床和经济结局。在总体滤泡性淋巴瘤队列中，共有 1947 例患者：1294 例接受 R 为基础的治疗方案，653 例接受非 R 为基础的治疗方案。在强化 R 为基础治疗的第一年，接受 R 为基础治疗的患者住院次数更少，住院时间更短，但费用更高。年轻、女性患者以及在一线治疗中选择 R 为基础治疗方案的患者，其临床结局得到了改善。
